A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05765812 |
Recruitment Status :
Recruiting
First Posted : March 13, 2023
Last Update Posted : April 24, 2024
|
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date ICMJE | February 15, 2023 | ||||
First Posted Date ICMJE | March 13, 2023 | ||||
Last Update Posted Date | April 24, 2024 | ||||
Actual Study Start Date ICMJE | May 15, 2023 | ||||
Estimated Primary Completion Date | September 2028 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
|
||||
Original Primary Outcome Measures ICMJE | Same as current | ||||
Change History | |||||
Current Secondary Outcome Measures ICMJE |
|
||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title ICMJE | A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma | ||||
Official Title ICMJE | A Phase 1/2 Open-label Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma | ||||
Brief Summary | The primary purpose of Phase 1 (dose escalation) of this study is to identify the recommended Phase 2 dose (RP2D) of Debio 0123 in combination with temozolomide (TMZ) (Arm A) and in combination with TMZ and radiotherapy (RT) (Arm B) and to characterize the safety and tolerability of these combinations in adult participants with glioblastoma (GBM). The primary purpose of Phase 2 of this study is to assess the efficacy of Debio 0123 at the RP2D in combination with TMZ, compared to standard of care (SOC) in adult participants with GBM. |
||||
Detailed Description | Not Provided | ||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Phase 1 Phase 2 |
||||
Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Parallel Assignment Intervention Model Description: Parallel assignment applies to the arm groups within Phase 1 of the study. Sequential assignment will apply to Phases 1 and 2 of the study. Masking: None (Open Label)Primary Purpose: Treatment |
||||
Condition ICMJE |
|
||||
Intervention ICMJE |
|
||||
Study Arms ICMJE |
|
||||
Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Recruiting | ||||
Estimated Enrollment ICMJE |
120 | ||||
Original Estimated Enrollment ICMJE |
89 | ||||
Estimated Study Completion Date ICMJE | September 2028 | ||||
Estimated Primary Completion Date | September 2028 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Screening Inclusion Criteria for Phase 1 Arm A and Phase 2:
Additional specific inclusion criteria for Phase 1 Arm A and Phase 2:
Additional specific inclusion criteria for Phase 1 Arm A:
Additional specific inclusion criteria for Phase 1 Arm B:
Additional specific inclusion criteria for Phase 2:
Exclusion criteria for Phase 1 Arm A:
Exclusion Criteria for Phases 1 and 2:
Specific exclusion criteria for Phase 1 Arm A and Phase 2:
Specific exclusion criteria for Phase 1 Arm B:
Exclusion criteria for Phase 2:
[Note: Other inclusion/exclusion criteria mentioned in the protocol may apply.] |
||||
Sex/Gender ICMJE |
|
||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||
Accepts Healthy Volunteers ICMJE | No | ||||
Contacts ICMJE |
|
||||
Listed Location Countries ICMJE | Spain, Switzerland, United States | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT05765812 | ||||
Other Study ID Numbers ICMJE | Debio 0123-GBM-105 2022-502156-31 ( EudraCT Number ) U1111-1283-6423 ( Other Identifier: UTN Number (World Health Organization) ) |
||||
Has Data Monitoring Committee | No | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement ICMJE |
|
||||
Current Responsible Party | Debiopharm International SA | ||||
Original Responsible Party | Same as current | ||||
Current Study Sponsor ICMJE | Debiopharm International SA | ||||
Original Study Sponsor ICMJE | Same as current | ||||
Collaborators ICMJE | Not Provided | ||||
Investigators ICMJE |
|
||||
PRS Account | Debiopharm International SA | ||||
Verification Date | April 2024 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |